Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

y for Node-negative and 1-3 positive node Disease may Avoid ChemoTherapy) to determine the prospects of withholding chemotherapy and/or trastuzumab in HER2+, MammaPrint(R) low risk patients.

About MammaPrint(R)

MammaPrint(R) is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint(R) identifies patients with early metastasis--those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint(R) test result provides a doctor with a clear rationale to assess the benefit of adjuvant chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint(R) tests are conducted in Agendia's CLIA-certified service laboratory. All other breast cancer recurrence assays currently marketed have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care instruments and consumables for the medical, research, and ... the veterinary and research markets in the ... a stock purchase agreement to acquire 100% of QCR ... based distribution organization. The transaction closed on ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
(Date:11/21/2014)... N.Y. , Nov. 21, 2014  Cardinal Health, ... world,s largest health care services companies, and Henry Schein, ... provider of health care products and services to office-based ... the companies have entered into a long-term strategic agreement ... product offerings to office-based medical practices.  This strategic agreement ...
Breaking Medicine Technology:Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... In the year since a devastating earthquake struck Haiti on ... world have launched and supported projects to help the country ... began, Rotary clubs started a $200,000 initiative to implement cholera ... waterborne disease. Rotary clubs worldwide have contributed more ...
... Cardinal Health plans to release second-quarter financial results for its ... of trading on the New York Stock Exchange. ... Feb. 3 at 8:30 a.m. EST to discuss second-quarter results. ... the Investor page at cardinalhealth.com/investors or dial 857-350-1669 passcode 24786608. ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3Cardinal Health to Release Second-Quarter Results on Feb. 3 2
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... Cancer researchers in New York and ... communication tunnels and the growth and spread of mesothelioma. ... on the Surviving Mesothelioma website. , Doctors at ... Minnesota have just released their study on tunneling nanotubes ... cells. They found that mesothelioma cells contain ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of ... promotion of mag locks for glass doors online. In ... on these fresh products. Customers can get more information ... doors are in excellent performance. Customers who want to ... soon as possible. They also can enjoy the ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
(Date:11/22/2014)... PA (PRWEB) November 22, 2014 "My ... the pain caused by the machine," said an inventor ... she had to go back a second time because ... invention idea." , She developed the patent-pending MAMO EASY ... breast cancer. The design saves the patient from the ...
Breaking Medicine News(10 mins):Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
... ... Club, the Endangered Habitats League and SOS Hills will honor "Avatar" ... Outstanding Social Responsibility in Media. "Avatar,s" themes closely mirror the ... residents are facing against Granite Construction, a powerful corporation that wants ...
... ... medical experience. , ... Scottsdale, AZ (PRWEB) March 3, 2010 -- NightHawk Radiology Services, the leading ... named two new physician leaders to its Medical Executive Team (MET), an influential group ...
... , ... ... ... ...
... ... ... ... ...
... forms of Leukaemia have identified a new drug target to ... diseased cells. The research, reported in EMBO Molecular Medicine ... if targeted could prevent diseased cells from developing. The ... Vienna, carried out their research on acute lymphoid leukaemia (ALL) ...
... from injuries to the distal biceps tendon may benefit from ... review article published in the March 2010 issue of the ... (JAAOS). Located in the front of the elbow, the distal ... muscle, and is responsible for two primary motions: , ...
Cached Medicine News:Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 2Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 3Health News:Temecula Environmental Groups & City to Honor "Avatar" Director James Cameron with First Ever Environmental Media Award 4Health News:NightHawk Radiology Services Expands Its Medical Executive Team 2Health News:NightHawk Radiology Services Expands Its Medical Executive Team 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 2Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 3Health News:VIDEO from Medialink and Juice Products Association: Teens Who Drink Juice Have Healthier Diets, Eat More Whole Fruit 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 2Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 3Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 4Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 5Health News:Diplomat Specialty Pharmacy Gets Aggressive in Seeking Funding Sources for Life Saving Drugs 6Health News:Targeting leukemia cell's gene 'addiction' presents new strategy for treatment 2Health News:Battling a biceps injury 2Health News:Battling a biceps injury 3
... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
This optimal design addresses low-cost, simple, non-invasive ankle distraction....
Medicine Products: